Abstract
BackgroundFDA-approved monoclonal antibodies (mAbs) that recognize the ganglioside GD2 (glycolipid) are used in the treatment of high-risk neuroblastoma (NBL). Despite successful integration of anti-GD2 mAbs into upfront treatment protocols, 40–50%...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
